Davis Rea’s Biogen BIIB Stock Holding History

Davis Rea’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-7,445	Closed	-$2.17M	–	45
2015 Q3	$2.17M	Buy	7,445 +2,312	+45%	+$764K	1.32%	23
2015 Q2	$2.07M	Buy	5,133 +138	+3%	+$55.4K	1.27%	23
2015 Q1	$2.11M	Buy	+4,995	New	+$1.97M	1.37%	23

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Davis Rea's BIIB Position: Q4 2015 in Review

Davis Rea sold out of Biogen (BIIB) in Q4 2015, closing a stake of 7,445 shares — an estimated $2.17M sold.

Davis Rea first reported a position in BIIB in Q1 2015 and held it in 3 quarters. The position peaked at $2.17M in Q3 2015. 969 funds tracked by Wall St. Rank hold BIIB as of Q4 2015.

Davis Rea reported no remaining Biogen position as of Q4 2015 after selling out during the quarter.
Davis Rea sold 7,445 Biogen shares in Q4 2015, an estimated $2.17M.
Davis Rea first reported a position in Biogen in Q1 2015 and held it in 3 quarters.
Davis Rea's Biogen position peaked at $2.17M in Q3 2015.
969 funds tracked by Wall St. Rank held Biogen as of Q4 2015.

Based on Davis Rea's 13F filing for Q4 2015, filed 9 Feb 2016.